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Abstract
Background: Nasal allergen challenge (NAC) is useful to study the pathophysiology of rhinitis, and multiple
challenges may more adequately approximate natural exposure.
Objective: To determine the effect of 4 consecutive daily NAC, on clinical and inflammatory parameters in rhinitics
with or without asthma.
Methods: Rhinitic subjects were recruited: 19 with mild asthma and 13 without asthma. Subjects underwent a
control challenge (normal saline) followed by 4 consecutive daily NAC. Allergen challenge consisted of spraying
the chosen allergen extract into each nostril until a positive nasal response occurred. Symptoms were recorded on
a Likert scale, and oral peak expiratory and nasal peak inspiratory flows allowed assessment of a nasal blockage
index (NBI), for a period of 7 hours. Induced sputum and nasal lavage were performed on control day and after 1
and 4 days of NAC.
Results: Compared with the control day, there was a significant increase in symptom scores and NBI 10 minutes
after each last daily NAC in both groups (p < 0.05). Symptom scores and NBI were similar for the 2 groups, except
for nasal obstruction and rhinorrhea, which were more marked in subjects with asthma and rhinitis, respectively.
Nasal lavage eosinophils were increased after 4 days of challenges in both groups, but there was no change in
sputum eosinophils. No cumulative effect or any late response were observed in any of the groups over the
challenge period.
Conclusion: Multiple NAC may be a useful tool to study the pathophysiology of allergic rhinitis or its relationships
with asthma.
Trial registration: ClinicalTrials.gov NCT01286129
Background
Asthma and rhinitis are two airway inflammatory dis-
eases that often coexist in the same patient. Up to 80% of
asthmatic patients also sufferf r o ma l l e r g i cr h i n i t i s[ 1 , 2 ]
a n dt h er i s kt od e v e l o pa s t h m ai sa l m o s tt h r e et i m e s
higher among allergic rhinitic subjects compared to con-
trols [3]. Asthma and allergic rhinitis involve common
inflammatory mediators that may contribute both to
u p p e ra n dl o w e ra i r w a yi n f l a m m a t i o n[ 4 ] .T h e s e
epidemiological and pathophysiological observations sup-
port the concept of the ‘United Airways’ hypothesis in
which upper and lower airways should be considered as a
continuum, rather than 2 distinct units [5,6]. However,
the mechanisms by which some rhinitic subjects will sub-
sequently develop asthma are still to be understood.
Several techniques have been developed to study the
clinical and pathophysiological mechanisms of allergic
rhinitis. Among those commonly being used are direct
challenges to histamine or allergens, and natural expo-
sure models [7]. Nasal allergen challenge (NAC) is a
well-recognized model that has the advantage of repro-
ducing a direct allergen contact in a controlled setting,
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subjects with standardized allergens. In comparison with
challenges in exposure units, NAC helps to understand
specifically the effect of challenging the upper airways
on systemic or lower airway inflammation, since the
allergen is delivered locally in the nose. This method
seems therefore appropriate to study the link between
an upper airway disease, such as allergic rhinitis, and a
lower airway disease, such as asthma.
Single dose NAC may limit the efficiency of this
model, since it may not reproduce the chronicity of a
natural allergen exposure. In the past, conflicting results
were obtained regarding the impact of upper airway
inflammation on the induction of lower airway inflam-
mation using single dose NAC [8,9]. The need to find a
model closer to natural allergen exposure has led to the
development of repeated allergen challenges [10]. These
challenges consist of performing a daily challenge with
the chosen allergen and to repeat the procedure over a
few consecutive days [10]. This type of challenge has
previously been used to investigate the efficiency of dif-
ferent therapies in subjects suffering from seasonal aller-
gic rhinitis [11-13], although it could also be helpful to
compare the type of clinical response in allergic rhinitics
with or without asthma.
To our knowledge, no studies are available to compare
the effect of repeated nasal allergen challenges in non-
asthmatic and asthmatic rhinitic subjects. The aim of
the present study was therefore to compare the effects
of a repeated daily NAC with perennial standardized
allergens, on clinical and inflammatory parameters,
between allergic rhinitic subjects with or without
asthma. This study could also help to compare the nasal
response of these 2 groups in regard to a possible
cumulative effect, the presence of a late response and
the type of response.
Methods
Subjects
Thirty-two non-smoking subjects were recruited: 19 had
mild stable asthma associated with allergic rhinitis (A) and
13 had allergic rhinitis without asthma (R). Rhinitis was
defined according to the ARIA guidelines [14]. All subjects
had a positive reaction to cat hair and/or house dust mite
(Dermatophagoides pteronyssinus) aeroallergens on allergy
skin prick tests and reported rhinitis symptoms when
exposed to an environment containing this allergen.
Asthma was defined according to the criteria proposed by
the American Thoracic Society (ATS) [15]. At entry into
the study, all subjects had baseline forced expiratory
volume in one second (FEV1) >70% predicted. Asthmatic
subjects had a provocative concentration of methacholine
causing a 20% fall in FEV1 (PC20) ≤ 16 mg/mL and non-
asthmatic subjects had a PC20 >16 mg/mL.
Subjects who had received oral or inhaled corticoster-
oids in the past 6 months, nasal corticosteroids in the
past 3 months, and anti-inflammatory or antihistamine
d r u g si nt h ep a s t7d a y sw e r ee x c l u d e df r o mt h es t u d y .
Asthmatic subjects did not use any rescue medication 7
hours prior to each visit and 7 hours following every
challenge. None of the subjects experienced upper or
lower respiratory tract infection within one month pre-
ceding the beginning of the study. All subjects provided
a written informed consent and the study was approved
by the institutional Ethics Committees (Institut universi-
taire de cardiologie et de pneumologie de Québec and
McMaster University).
Study design
The study design is presented in Figure 1. The study
was performed outside the pollen season. On a baseline
visit, 2 to 7 days prior to control challenge, allergy skin
prick tests and methacholine inhalation challenge were
done. Subsequent to baseline visit, a control challenge
was done, followed, a week later, by repeated NACs.
NACs were performed over 4 consecutive days, in the
morning. Nasal peak inspiratory flows (NPIF), oral peak
expiratory flows (PEF), and symptoms were recorded at
baseline and at regular intervals over 7 hours post-chal-
lenge on each challenge day. Induced sputum and nasal
lavage specimen were obtained 7 hours following the
control challenge and the first and last NAC.
Figure 1 Study design. The protocol was divided into 3 different parts: a baseline visit, a control day (nasal challenge with 0.9% saline) and 4
consecutive days of nasal allergen challenge (days 1-4).
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Atopy was determined using skin prick tests procedure
for common aeroallergens. Normal saline and histamine
were used as negative and positive controls, respectively.
Skin wheal diameter was recorded at 10 minutes as the
mean of 2 perpendicular measurements. A positive
response was defined as a skin wheal diameter of 3-mm
or more compared to negative control. The choice of
the allergen for NAC, either cat hair or D. pteronyssinus,
was based upon the intensity of the sensitization, deter-
mined by skin prick tests, and questions to the subjects
about their rhinitis symptoms to these allergens.
Skin prick titration was done prior to allergen chal-
lenge in order to determine the starting allergen con-
centration for NAC. The titration was completed in the
same way as for skin prick tests, but using a series of
dilutions of the chosen allergen. The procedure was
done in duplicate. The concentration that yielded a skin
prick test of 2-mm minimum was the chosen starting
concentration for nasal challenge.
Spirometry and methacholine inhalation challenge
Baseline FEV1 and forced vital capacity (FVC) were
measured according to the ATS criteria [16] and pre-
dicted values were obtained from Knudson [17]. Metha-
choline bronchial challenge was done as described by
Juniper [18].
Nasal challenge
NAC was performed as previously described by Wilson
et al. [9] using perennial allergens (cat hair, 10,000
BAU/mL or D. pteronyssinus,3 0 , 0 0 0A U / m L ;O m e g a
Laboratories, Montreal, QC, Canada). Briefly, the nasal
control challenge was done using 4 exposures of 0.9%
saline at 10 min intervals in the same way as for aller-
gens. Nasal allergen challenge was done using tenfold
increasing concentrations of the allergen extract chosen,
either cat hair or D. pteronyssinus, beginning with the
concentration pre-determined by skin titration. Before
spraying, subjects were asked to inhale through their
mouth to total lung capacity and to hold their breath, in
order to avoid lower airway contamination by the test
agent [8,19]. Then, one squirt (0.1mL) of the starting
concentration was sprayed into each nostril from a
metered-dose pump spray (Aventis Pharma, Laval, QC,
Canada).
Symptom scores derived from: blockage 0-2 (absence
= 0, moderate = 1, severe = 2), secretion 0-2 (absence =
0, moderate = 1, severe = 2), sneezing 0-2 (< 3 sneezes
= 0, 3-5 sneezes = 1, > 5 sneezes = 2), itching eye or
throat 0-1 (absence = 0, presence = 1), and conjunctivi-
tis, cough, urticaria or dyspnea 0-1 (absence = 0, pre-
sence = 1), were recorded 10 minutes after each
provocation. The total score of symptoms was calculated
by adding the scores up to a maximum score of 8. The
procedure was repeated with tenfold increasing concen-
trations until the highest concentration was given or a
positive response occurred. A positive response was
achieved when the total score of symptoms reached a
minimum of 3 points. If this was not obtained with the
highest concentration, then the dose was increased by
giving 2 squirts and, if necessary, 3 squirts in each
nostril.
Nasal obstruction was measured quantitatively using
NPIF and PEF before provocation and at determined
time-points for 7 hours post-provocation. At these same
time-points, subjects evaluated the intensity of their
symptoms for nasal obstruction, rhinorrhea, sneezing,
nasal itching, and cough. A score was given for each of
these symptoms, using a 7-point Likert scale, graduated
from 0 = Not troubled, to 6 = Severely troubled.
Peak Flows
NPIF was measured with a nasal peak flow meter (In
Check, Clement-Clarke International Ltd, Harlow, Essex,
UK), using the method previously described by Youlten
[20]. The best of three measurements was recorded. The
use of NPIF and PEF (Mini Wright Peak Flow Meter,
Clement-Clarke) allowed obtaining the nasal blockage
index (NBI), using a modified equation from Taylor et
al. [21]:
NBI =
PEF - NPIF
PEF
Nasal Lavage
Nasal lavage was performed as described by Cormier et
al. [ 2 2 ] .B r i e f l y ,s u b j e c t sw e r e in a sitting position with
the neck flexed at 45° from horizontal. Subjects were
asked to blow their nose before 5 mL of phosphate buf-
fered saline (PBS) solution were instilled into each nos-
tril with a needleless syringe. Subjects then flexed the
neck and expelled nasal lavage fluid into a sterile dish.
Throughout the procedure, subjects were asked to
refrain from breathing or swallowing. Lavage fluid was
filtered and centrifuged. Supernatant was aliquoted and
frozen until further analyses. Cells were resuspended
and counted to determine total cell count and viability.
Slides were then prepared and stained with Diff-Quik
for differential cell count.
Induced Sputum
Sputum induction was performed using the method
described by Pin et al. [23] and modified by Pizzichini
et al. [24]. Sputum was processed within 2 hours follow-
ing induction. Briefly, mucus plugs were selected from
saliva, weighed, treated with 4 times their volume of
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reaction was stopped with an equal volume of Dulbec-
co’s phosphate buffered saline (D-PBS) 1X, filtered and
counted to determine total cell count and viability. Sus-
pension was adjusted to 1 × 10
6 cells/mL and 2 slides
were prepared and stained with Diff-Quik for differential
cell count. Following centrifugation, sputum superna-
tants were aliquoted and frozen.
Mediator measurements
The presence of eosinophilic cationic protein (ECP) in
nasal lavage and induced sputum supernatants was mea-
sured by ELISA (Measacup ECP, MBL International
Corporation, Woburn, MA) according to manufacturer’s
instructions. Nasal lavage samples were processed non-
diluted and sputum samples were diluted 1:75. The
detection limit of the assay was 0.125 ng/mL.
Statistical Analysis
Values are reported as mean ± SEM. Two different sta-
tistical procedures were completed 1) to compare asth-
matic to rhinitic subjects over a time course at specific
visits, 2) to compare asthmatic to rhinitic subjects over
at i m ec o u r s ef r o md i f f e r e n tv i s i t s .1 )W ec o n s i d e r e d
subjects as random block effects. For each visit, values
were measured at time 0, 10, 20, 30, 45 min, 1h, 1.5h,
2h, 3h, 4h, 5h, 6h, and 7h. The statistical approach used
was to perform a three-way repeated measures design
w h e r eg r o u pa n dt i m ew e r ea n a l y s e da sf i x e df a c t o r s .A
symmetric component variance-covariance structure was
defined to analyse repeated measurements as time
points were not equally spaced. The multivariate nor-
mality was verified using Mardia’s test. 2) We consid-
ered subjects as random block effects. The statistical
approach used was to perform a four-way doubly-
repeated measures design where group, visit, and time
were analysed as fixed factors. The unstructured com-
pound symmetry structure was used to analyse repeated
measurements. Tukey’s comparisons were performed to
compare visits and time points. The multivariate nor-
mality was verified using Mardia’s test. The results were
considered significant with p-values ≤ 0.05. The data
were analysed using the statistical package program SAS
v9.1.3 (SAS Institute Inc., Cary, NC)
Results
Subjects
The characteristics of the subjects are presented in
Table 1. Age and baseline FEV1 were similar between
the 2 groups. Lower initial dilutions of allergen given for
challenge were used for asthmatics compared to rhini-
tics. Allergens used for challenge were equally distribu-
ted within and between groups.
Nasal blockage index
Over the 4 challenge days, no differences in baseline
NBI values were detected between and within subjects,
irrespective of their group (Figure 2). On control day,
no significant change in NBI was observed over time
and the response was similar between groups. Ten min-
utes after obtaining a positive response on each allergen
challenge day, an increased NBI value was observed for
the two groups compared with baseline value (p < 0.05)
and the response was similar for the 2 groups. More-
over, the comparison of each allergen challenge day
with control day showed a significant increase in NBI
from 10 min to 1.5h post-challenge.
Symptom scores
All subjects recorded their symptoms for a 7-hour per-
iod post-challenge. In regard to nasal obstruction score,
on control day, no symptoms were observed for any of
the 2 groups. When comparing each allergen challenge
day with control day, the score remained significantly
increased until 1.5h post-challenge for the 2 groups (p <
0.05). Overall, asthmatic subjects had a higher nasal
obstruction score than rhinitics (p = 0.04).
No symptom of rhinorrhea was observed on control
day in any of the 2 groups, while a significant increase
was observed until one hour post-challenge on each
allergen challenge day, in comparison with control day,
for both rhinitics and asthmatics (p < 0.05). Overall,
subjects with rhinitis alone had a higher rhinorrhea
score than those with rhinitis and asthma (p = 0.03).
Table 1 Characteristics of subjects
n Rhinitics 13 Asthmatics 19
*Age (years) 24 (19-32) 24 (19-41)
**Gender (M: F) 7: 6 5: 14
**Allergen used for NAC (Cat hair: D.pteronyssinus) 5:8 1 1:8
**Initial dilution given (non-diluted, 1:10, 1:100, 1:1000) 1, 5, 2, 5 0, 3, 5, 11
*FEV1 (% predicted) 108 (87-125) 103 (87-125)
*Data are presented as mean (range)
** Data are presented as number of subjects
FEV1: Forced expiratory volume in one second
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until one hour following allergen challenge for rhinitics
and for 30 minutes following challenge for asthmatics,
compared with control day. Overall, no significant dif-
ference was observed between groups (p > 0.05).
No significant change for sneezing and cough symp-
tom scores were observed on any of the 4 allergen chal-
lenge days in the two groups, compared with control
day. However, we observed that a limited number of
subjects experienced cough symptoms at least at one
time-point on allergen challenge days (A = 9/19 (47%)
and R = 7/13 (54%)).
No late response was observed in any of the two
groups during the challenge period.
Upper and lower airway inflammation
Data for changes in inflammatory parameters after 1
and 4 days of nasal allergen challenges are presented in
Table 2. There was a significant increase in the percen-
tage of eosinophils in nasal lavage after 4 days of nasal
allergen challenges in rhinitics and asthmatics compared
with control challenge (p < 0.05). The levels of ECP in
nasal lavage were significantly increased after 1 day of
nasal allergen challenge in both groups (p < 0.05), but
not after 4 days. There was no inflammatory change in
the percentage of eosinophils and in ECP levels in
induced sputum after both the first and last allergen
challenges compared with control challenge.
Discussion
Nasal challenges performed on a single occasion may
not represent accurately a natural allergen exposure,
leading to the development of multiple challenges, done
over a few consecutive days, which could be more repre-
sentative of the reality. This type of nasal challenge has
been used in few studies in the past [11-13,25]. In these,
only allergic rhinitic subjects were recruited and three
out of four were done to compare the effect of different
types of rhinitis medications [11-13]. To our knowledge,
t h ep r e s e n ts t u d yi st h ef i r s tt oc o m p a r et h ee f f e c t so f
multiple NAC in rhinitic subjects with or without
asthma.
One objective of this study was to determine how
allergic rhinitic subjects with or without asthma would
react following a multiple NAC, regarding the type and
duration of induced symptoms. Our results showed that
the two groups responded in the same way, except for
nasal obstruction and rhinorrhea symptoms. Asthmatics
were more likely to report nasal obstruction, whereas
rhinitics had more symptoms of rhinorrhea. This is of
interest, since nasal obstruction may lead to mouth
breathing, allowing an increased quantity of allergens to
penetrate into the lower airways, inducing inflammation,
and potentially triggering asthma symptoms.
The other objective was to compare the inflammatory
response of allergic rhinitic subjects with or without
asthma following a repeated nasal allergen challenge.
We observed a significant increase in nasal lavage ECP
concentrations in both groups after 1 day of challenge,
which was no more significant after 4 days of challenge.
Furthermore, an increase in upper airway eosinophils
after 4 days of challenge was observed in both groups.
No significant difference in upper airway inflammation
was observed between groups. We did not observe a sig-
nificant change in lower airway inflammation following
neither the first nor the last allergen challenge, deter-
mined by sputum eosinophils and ECP. There was no
significant difference in lower airway inflammation
between groups. However, since upper airway inflamma-
tion appeared only at the last challenge day, we think
that it could be of interest to continue this type of chal-
lenge over a few more days to be able to induce lower
Figure 2 Effect of nasal challenge with saline (control day) or
allergen (days 1-4) on NBI. (a) for rhinitics and (b) for asthmatics
at 0 min and over 7 hours post-challenge. *p < 0.05; 0 min vs 10
min on days 1-4. **p < 0.05; Control day vs days 1-4.
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possibly observe a different inflammatory profile
between groups.
We used perennial allergens (cat hair and D. pteronys-
sinus) to perform allergen challenges since these aller-
gens are more associated with lower airway
hyperreactivity [13] and lower airway inflammation than
outdoor ones [26]. Therefore, it is of interest to observe
the effect of upper airway challenge with perennial aller-
gens on lower airway symptoms given that, to our
knowledge, no study used perennial allergens to perform
multiple nasal allergen challenges. A limited number of
subjects experienced cough symptoms following nasal
challenge, reflecting the link between upper airway sti-
mulation and lower airway symptoms. Further studies
are needed to determine if rhinitic subjects experiencing
these symptoms are more at risk to develop asthma.
Several techniques have been used to deliver allergens
to the nose [27]. In our study, the nasal pump spray
technique was used for two main reasons. First, it has
the advantage of delivering the allergen over the entire
nasal mucosa, instead of a localized area, as it can be
observed, for example, with pipettes or paper discs [28].
Second, we know the exact quantity of solution sprayed
into the nose. With the pump spray delivery method, no
allergen should penetrate in the lower airways if the
subjects previously inhaled to total lung capacity and
held their breath before spraying the solution [19]. We
believe that the results obtained in our study are the
specific consequences of upper airway stimulation.
The challenge was repeated over 4 consecutive morn-
ings allowing to determine if there was a priming effect.
This effect was first described by Connell as the ability
to use smaller amounts of allergen in subsequent chal-
lenges to induce the same or greater degree of sympto-
m a t i ca l l e r g i cr e s p o n s e[ 2 9 , 3 0 ] .T h i so b s e r v a t i o nw a s
then confirmed by others [31]. However, although this
concept is now well accepted, it seems that repeated
allergen challenge and priming are not necessarily linked
[10]. Several factors play a role in nasal priming, one of
which is the way the response is recorded. The strongest
evidence of priming comes from changes in mediator
levels and inflammatory cell numbers in the nose, which
do not always coincide with physiological or clinical
changes. In our study, when looking at symptoms scores
or NBI results, this effect was not observed between the
4 days of challenge, in any of the two groups. However,
in both groups, we did observe an increase in nasal
lavage eosinophils over the study period that reached
significance at day 4 of challenge. ECP levels also signifi-
cantly increased on the first day of challenge compared
with control day in both groups, but no further increase
was observed at day 4, although levels were still higher.
This is suggestive of priming at the immunological level,
as also shown by McDermott et al.,w h op e r f o r m e d
repeated allergen challenge over 8 consecutive days,
recording symptoms scores and collecting samples at
day 2 and 24h following the last challenge (day 9) [32].
In that study, they did not observe further increase in
symptoms scores between day 2 and day 9 of allergen
challenge, but reported an additional increase in IL-5
and a decrease in IFN-g at day 9 compared with day 2.
In addition, as suggested by Wachs et al., a priming
response may be observed overall, but there is a large
variety in individual response patterns to repeated aller-
gen provocation [25].
We did not observe the development of a late nasal or
bronchial response in the hours following the chal-
l e n g e s ,e v e no nt h el a s tp r o v o c a t i o nd a y .T h e r ei sal o t
of variability in late nasal allergic response prevalence
ranging between 30% and 50% [33]. The intensity of the
immediate reaction cannot be considered to be a suita-
ble predictor of the late response [33]. Various factors
such as the differences in challenge procedure, the data
recording techniques and the cut-offs for positivity can
be involved, although the mechanisms have not been
fully clarified [33]. In the present study, subjects were
recording their symptoms scores and NPIF hourly, until
7 hours post challenge. Late responses can be observed
between 3 and 8 hours post exposure to the allergen.
An extension in the collection of data over 7 hours
post-challenge could have allowed to observe a late
response in some subjects, although unlikely. We
observed an increase in nasal lavage eosinophils only
following 4 days of challenge, but it is possible that the
inflammatory response was not strong enough to induce
Table 2 Inflammatory parameters following nasal control challenge, and 1 and 4 days of nasal allergen challenges
Parameter Rhinitics Asthmatics
Control Day 1 Day 4 Control Day 1 Day 4
Nasal lavage eosinophils (%) 1.3 ± 0.9 3.0 ± 1.3 15.5 ± 9.6 * 2.1 ± 0.6 7.5 ± 4.3 15.7 ± 5.4*
Nasal lavage ECP (ng/mL) 3.8 ± 1.5 8.7 ± 3.4 * 7.9 ± 2.6 8.6 ± 3.2 10.3 ± 2.7 * 9.4 ± 4.0
Induced sputum eosinophils (%) 2.0 ± 1.3 1.3 ± 1.5 1.6 ± 1.0 5.6 ± 1.8 6.0 ± 1.7 4.1 ± 1.4
Induced sputum ECP (ng/mL) 72 ± 20 112 ± 41 98 ± 36 146 ± 43 171 ± 41 242 ± 106
Data are presented as mean ± SEM
* p < 0.05 vs control challenge
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decrease in NPIF.
To be sure that the results were not influenced by
outdoor allergens, subjects sensitized to seasonal aller-
gens were tested out of the pollen season. We are
aware that some indoor allergens, such as dust mites,
cannot be avoided completely. In this regard, we asked
the subjects to keep their life habits as stable as possi-
ble throughout the study. In addition, we compared
the allergen challenge results with the control chal-
lenge results, which were done in the same way. These
precautions helped to better assess the specific effect
of the allergens tested, independently of the presence
of perennial allergens in the subjects’ environment.
However, we cannot exclude the possibility of interfer-
ence of such continuous exposure to perennial aller-
gens with the clinical response to allergen challenge.
Indeed, Reinartz et al. showed that subjects mono-sen-
sitized to grass pollen had lower nasal symptom scores
and NPIF following nasal challenge than subjects
mono-sensitized to HDM or poly-sensitized subjects
[34]. This could not be explained by serum levels of
total or specific IgE, suggesting that altered local
immune-regulatory processes could be involved. How-
ever, the influence of pattern or sensitization on the
late-phase response was not studied. In addition, the
same dose of allergen was administered to all subjects
while some subjects might have needed a lower dose
to induce an early response. Since cat hair and HDM
are known to be potent inducers of the late response
in bronchial allergen provocations and as we induced a
significant upper airways clinical response, it is unlikely
that the choice of allergen is responsible for the lack of
late response in this study.
Conclusions
This study shows that multiple nasal challenges with
p e r e n n i a la l l e r g e n si n d u c em o r er h i n o r r h e ai nr h i n i t i c
subjects without asthma and more nasal obstruction in
rhinitic subjects with asthma, suggesting a different
symptomatic profile between these 2 groups. We found
no evidence of cumulative effect or late response after
multiple nasal challenges in both groups.
In conclusion, we think that this method could be
useful to assess the effect of treatment on symptoms.
However, future studies are needed to improve this pro-
tocol of repeated nasal allergen challenge to induce
lower airway inflammation, maybe by extending the
challenge period or increasing the doses given.
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